Q-omics provides the consensus-scored MED20 profile across patient tissues and cancer cell-line models. MED20 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MED20 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MED20 protein abundance shows 21,519 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where MED20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED20 survival associations across molecular data types. MED20 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED20 RNA expression–survival associations across cancer types. High MED20 expression shows unfavorable associations in SKCM, LIHC, LAML and KICH, but favorable associations in KIRC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MED20 RNA expression.
This table summarizes MED20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MED20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED20 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, LUAD, LIHC and COAD. The HNSC box plot shows higher MED20 RNA expression in tumor versus normal tissue (log2 FC = +1.071, t-test p < 0.001).
This table shows molecular features associated with MED20 in patient tissues and cancer cell lines. In patient samples, MED20 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and PANCREAS.
